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Abstract
Background Children with unilateral Wilms tumor (WT)
treated with chemotherapy and/or radiotherapy and nephrec-
tomy have excellent survival rates. A solitary functioning kid-
ney (SFK) is associated with progressive renal injury. This
study aims to investigate the additional effect of Wilms tumor
treatment on renal function compared with children with an
SFK for non-oncological reasons.
Methods A single-center retrospective cohort study on the
renal injury markers of 79 survivors of unilateral WT was
performed and compared with a matched group of children
with an SFK for non-oncological reasons.Mean age at follow-
up was 12.4 (SD 5.9) years.
Results During follow-up, mean estimated glomerular filtra-
tion rate (eGFR) and blood pressure z-scores remained stable
at an acceptable level. However, in the group of 31 WT
patients with a follow-up of 15 years, 23 % showed signs
of renal injury. This proportion was smaller than the 54 %
in a group of SFK patients based on non-oncological causes
(p=0.004).
Conclusions A significant proportion ofWTsurvivors develop
renal injury during follow-up. Our data may be an underesti-
mation of the true frequency of progressive renal injury, due to a
lack of information on proteinuria. As with patients with a non-
oncological SFK, long-term follow-up is essential to monitor
WT survivors.
Keywords Wilms tumor . Solitary functioning kidney .
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Introduction
In recent years, it has become clear that a solitary functioning
kidney (SFK) from birth or acquired during childhood leads to
progressive renal injury [1, 2]. In the Kidney of MONo-
functional Origin (KIMONO) study cohort of over 400 chil-
dren with an SFK, one in three children showed signs of
progressive renal injury (hypertension, proteinuria, and/or
drugs prescribed for either of the two indications) during
childhood [1, 2]. As described by Brenner et al. [3], this is
hypothesized to be based on glomerular hyperfiltration, which
results in glomerular hypertension and damage. In addition, a
long-term follow-up study of patients with an SFK showed
that 20–50 % were dependent on renal replacement therapy at
the age of 30 years [4]. These data illustrate that an SFK in
childhood may have serious long-term consequences.
One of the reasons for an acquired SFK is a unilateral
Wilms tumor (WT). It accounts for 6 % of all childhood ma-
lignancies, with the highest incidence rate between 2 and
5 years of age, and a rare occurrence in adolescents or adults
[5]. The outcome of patients with WT has significantly im-
proved over the past decades. Five-year overall survival esti-
mates now range from 80 to over 95 %, depending on the
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stage and histology [6–8]. Chemotherapy and radiotherapy
may be harmful to the remaining kidney, but in general the
decrease in renal function is believed to be temporary and
reversible, and only present during chemotherapeutic treat-
ment [9]. The hyperfiltration hypothesis can also be expected
to apply in WT survivors. Green recently reviewed studies on
renal dysfunction in WT survivors [9]. Unfortunately, these
studies are small with heterogeneous patient populations and
with different methods of measuring renal function. In addi-
tion, in most SFK follow-up studies, WT patients are exclud-
ed, which makes the long-term outcome of having an SFK
after tumor nephrectomy together with chemo- and/or radio-
therapy compared with SFK after non-oncological causes un-
known. We hypothesize that children with an SFK after WT
have a decreased renal outcome compared with non-WT post-
nephrectomy subjects, resulting in a higher rate of hyperten-
sion, proteinuria, and/or reduced glomerular filtration rate
(GFR). This study aims to investigate the additional effect of
WT treatment on long-term renal function compared with




All survivors of unilateral WT, diagnosed between 1987 and
2011 at the Radboud University Medical Center from whom
follow-up data were available, were included in our study.
Data were retrospectively collected at four set time-points,
i.e., after 2.5, 5, 10, and 15 years of follow-up, and were
compared with those of matched children with SFK for non-
oncological reasons from the KIMONO cohort [2]. Patients
with a renal tumor other than WT were excluded from the
study, as were patients with associated syndromes such as
WAGR (WT, aniridia, genitourinary malformation, and men-
tal retardation) and Denys–Drash syndrome.
Data collection
All data were collected from the patient records using a case
record form. Tumor and treatment characteristics were collect-
ed from each patient. At diagnosis and at every follow-up time
point, medical examination, laboratory and/or radiology data
were recorded. During follow-up, standard medical examina-
tion and renal laboratory testing (serum creatinine, urine albu-
min–creatinine or protein–creatinine ratio or urine dipstick)
were collected when available. Differentmethods of determin-
ing creatinine levels were used. Unfortunately, there were in-
sufficient data on proteinuria and renal length to evaluate as a
separate marker. When no data were available, these were
considered to be within the normal range to prevent the
overestimation of renal injury. The GFR was estimated
(eGFR) using the revised Schwartz formula: eGFR
(ml*min−1*1.73 m−2)=k×height (m)/serum creatinine [in
mg/dL]), with a κ value of 41.3 [10]. Blood pressure (BP)
was measured using either a manual auscultatory or an auto-
matic oscillometric device. Neither the method nor the device
used was specified in the patient file. High BP was defined as
systolic BP (SBP) and/or diastolic BP (DBP) values above the
95th percentile (z-score >1.65) adjusted for age, gender, and
height [11]. Renal injury was defined as a reduced eGFR
(<60 ml*min−1*1.73 m−2), proteinuria and/or high BP, and/
or drug use to treat either proteinuria and/or high BP [12].
KIMONO cohort
The KIMONO cohort comprises the worlds’ largest cohort of
patients with an SFK. From the entire cohort of over 400
patients, the patients with matching characteristics were se-
lected (as far as possible). Criteria for the selection consisted
of the type of diagnosis (acquired SFK mainly based on the
nephrectomy of a previously functional kidney) and duration
of follow-up >10 years.
Statistical analysis
All data were analyzed using SPSS Statistics 18.0 (SPSS,
Chicago, IL, USA). Data were presented as number (%) or
mean (standard deviation, SD). The BP z-scores were calcu-
lated using percentile scores [11]. Differences between mea-
sured z-scores and expected (z-score=0) were calculated
using the one sample t-test. Comparison in eGFR between
different groups (gender, chemotherapy, disease stage) was
performed using one-way ANOVA. Comparison between
our cohort of WT survivors and the KIMONO cohort was
carried out using the independent samples t test. Statistical
significance was set at p<0.05.
Results
Patient characteristics
We were able to identify 108 patients who have been treated
for renal tumors at our institution. Figure 1 shows the inclu-
sion criteria. Seven patients were excluded because of non-
Wilms renal tumor (n=3, clear cell sarcoma), bilateral WT
(n=3), and horseshoe kidney (n=1). We were able to include
79WTsurvivors in our study for whom follow-up details were
available. Characteristics of the WT survivors and matched
KIMONO subjects are shown in Table 1.
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Renal function of WT survivors
Chart review of our WTsurvivors showed that renal function-
al analysis was mainly performed using SBP, DBP, and eGFR.
Unfortunately, there was insufficient data on proteinuria.
Table 2 shows renal function parameters of WT survivors at
the different follow-up time points. At diagnosis, mean SBP z-
score was 2.1 (SD 1.4) and DBP z-score was 1.8 (SD 1.3). At
follow-up, blood pressure returned to normal values. At dis-
charge from the hospital, mean SBP and DBP z-scores were
0.3 (SD 1.3) and 0.2 (SD 0.7) respectively. During follow-up,
BP z-scores remained stable on average and none of the sur-
vivors used renoprotective drugs during follow-up. The eGFR
remained stable over the follow-up period. There were no
significant differences in eGFR within the different treatment
protocols, gender or disease stage (data not shown), nor was
there an effect of radiation therapy.
Comparison with KIMONO study data
We compared renal function of WT survivors with a matched
group of SFK subjects from the KIMONO cohort (Table 3).
Despite the matching, the KIMONO patients were younger
than the WT survivors. The eGFR was similar in the cohort
of WT survivors and the KIMONO cohort and no significant
difference in SBP and DBP z-scores between the two cohorts
was noted. However, progressive renal injury was more fre-
quently found in the KIMONO cohort (54 %) than in the WT
survivors (23 %) after a follow-up of over 10 years.
Discussion
In this study, we showed that progressive renal injury in WT
survivors with SFK occurs in a similar manner to that in chil-
dren with SFK of non-oncological causes, even though the
frequency may be lower. Recently, a large cohort of more than
400 children with SFK was evaluated for signs of progressive
renal injury (KIMONO) [2].Wewere able to compare a small-
er cohort of WT survivors with a matched group from this
KIMONO cohort. This comparison showed that there was a
trend toward a higher frequency of high BP in the WT survi-
vors. However, none of the WT survivors was treated with
anti-hypertensive/anti-proteinuric drugs compared with 35 %
of the KIMONO cohort, which will have influenced the BP
readings at follow-up. In addition, proteinuria and/or albumin-
uria was not tested in most WT survivors, whereas 44 % of
individuals in the KIMONO cohort were found to have pro-
teinuria. These missing data may account for a large propor-
tion of the difference in frequency of progressive renal injury
between the two cohorts. Another explanation for the identi-
fied difference in renal injury may be the high prevalence of
associated congenital anomalies of the kidney and urinary
tract in patients from the KIMONO cohort. Indeed, it has been
shown that these associated malformations are an independent
risk factor for progressive renal injury [2]. Finally, a selection
bias in the KIMONO cohort may have accounted for a larger
than expected number of individuals with progressive renal
injury. The KIMONO cohort may be considered a biased co-
hort, as not all patients were included after a prenatal
Fig. 1 Patient inclusion criteria
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diagnosis, but may have been diagnosed based on clinical
characteristics (e.g., recurrent urinary tract infections or a pal-
pable abdominal mass). Even though previous analyses of
such bias have not been shown to result in different conclu-
sions, this has to be taken into account.
No difference in eGFR was found between the WT survi-
vors and the KIMONO cohort. As most WT patients received
drugs that were not directly nephrotoxic and the number of
high-risk patients who received carboplatin was relatively
small, this was in line with our expectations. The eGFR was
not significantly different between the different treatment
groups. However, subgroups of children treated with different
chemotherapeutic drugs were small; therefore, we may have
missed differences based on the sample size.
Green et al. recently reviewed the available evidence on pro-
gressive renal injury after successful treatment for ipsilateral non-
syndromic WT [6]. The risk of end-stage renal disease (ESRD)
20 years after diagnosis among children with unilateral, nonsyn-
dromic WT treated according to the National Wilms Tumor
Study Group protocols was 0.7 % [13]. Progressive renal injury
in WT survivors of a less serious degree is reported to be up to
30 % in survivors without abdominal irradiation and up to 40 %
in WT survivors with abdominal irradiation. In a large cohort of
adult survivors of different types of childhood cancer, low eGFR
was associated with treatment with unilateral nephrectomy, ab-
dominal radiation therapy, cisplatin, and ifosfamide [14]. Based
on data from reports from recent years (Table 4), hypertension
and albuminuria are found in 13 % of WT survivors at latest
follow-up, and 3 % had a clinically relevant reduced GFR. As
most reports do not describe a concurrence of renal injury
markers, it may be estimated from the recent literature that pro-
gressive renal injury is found in ±25%ofWTsurvivors, which is
in line with our results.
In daily pediatric care, equations that use creatinine to obtain
an eGFR have been widely adopted by clinicians, as recom-
mended by the Kidney Disease Outcome Quality Initiative
(K/DOQI) guidelines [12]; however, it has several limitations
compared with the gold standard measurement of GFR by inulin
clearance [15]. Westland et al. examined the precision of six
common estimating equations in predicting the gold standard
GFR, determined by an inulin single-injection method, in chil-
dren with an SFK [16]. They concluded that the combined
Table 1 Characteristics of Wilms tumor survivors and subjects from
the Kidney of MONo-functional Origin (KIMONO) cohort
Patient characteristics Wilms tumor KIMONO p
Number 79 184
Gender 0.04
Male 40 (50 %) 118 (64 %)
Female 39 (50 %) 66 (36 %)
Age at nephrectomy (years) 3.7 (SD 2.5) 4.2 (SD 4.6) 0.4
Age at latest follow-up (years) 12.4 (SD 5.9) 10.5 (SD 6.0) 0.02
Follow-up duration (years) 9.1 (SD 5.7) 6.9 (SD 5.1) 0.003
Side of tumor
Left 44 (56 %)
Right 35 (44 %)
Wilms tumor stage
I 39 (49 %)
II 15 (19 %)
III 17 (22 %)
IV 8 (10 %)
Histology at diagnosis
Low risk 9 (11 %)
Intermediate risk 54 (69 %)
High risk 8 (10 %)
Treatment protocola
SIOP 9 13 (17 %)
SIOP 93-01 31 (39 %)
SIOP 2001 35 (44 %)
Radiation therapyb 19 (24 %)
Reason for poor kidney function leading to nephrectomy
Congenital anomalies 32 (18 %)
Obstructive uropathy 41 (22 %)
Urinary tract infection 77 (42 %)
Posterior urethral valves 14 (7 %)
Miscellaneous 20 (11 %)
Data are presented as mean (standard deviation, SD) or as a number (%)
SIOP International Society of Pediatric Oncology
aNone of the patients was treated with ifosfamide
bNone of the patients received radiation therapy to the remaining kidney
Table 2 Renal function of Wilms tumor survivors at the different follow-up time points
Diagnosis Discharge 2.5 years 5 years 10 years 15 years
Age (years) 3.6 (2.4) 3.7 (2.5) 6.3 (2.5) 8.9 (2.8) 14.1 (2.5) 17.8 (3.6)
Systolic blood pressure (z-score) 2.1 (1.4) 0.3 (1.3) 0.0 (0.9) 0.2 (1.0) 0.6 (1.5) 0.6 (1.5)
Diastolic blood pressure (z-score) 1.8 (1.3) 0.2 (0.7) 0.8 (1.0) 0.1 (0.6) 0.0 (0.7) 0.0 (0.7)
eGFR (ml*min−1*1.73 m−2) 90 (36) 86 (21) 86 (25) 89 (23) 82 (22) 83 (14)
Data are presented as mean (standard deviation, SD)
eGFR estimated glomerular filtration rate
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serum cystatin C/serum creatinine/blood urea nitrogen (BUN)
Chronic Kidney Disease in Children (cKiD) equation estimates
the GFR of children with an SFK with superior precision.
However, when cystatin C is not available, eGFR–Schwartz
is an acceptable alternative. In most studies reporting on pro-
gressive renal injury in WT survivors, GFR has been estimated
using the Schwartz equation, as in our study. Different cut-off
values of eGFR are used to define renal injury. Green et al. [6]
used an eGFR of<80 ml*min−1*1.73 m−2 to define renal inju-
ry, whereas we used an eGFR of<60 ml*min−1*1.73 m−2, as
was recommended by the clinical practice guidelines for chron-
ic kidney disease in children and adolescents [12]. However, it
must be noted that the decline in eGFR due to glomerular
hyperfiltration is a relatively late phenomenon [17]. To detect
early deterioration in eGFR, it would therefore be interesting to
investigate more sensitive renal markers (such as fibroblast
growth factor [FGF] 23) in WT survivors during follow-up.
With excellent survival rates ofWT patients reaching 90%,
the identification and prevention of late effects due to treat-
ment are increasingly important. Life-long monitoring of WT
survivors based on the knowledge of the present study and of
previously described studies is warranted.
Nephron-sparing surgery (NSS) in unilateral WT patients
could potentially diminish progressive renal injury because of
the loss of nephrons [18]. Upfront chemotherapy and NSS
have been shown to provide safe and effective oncological
control, while optimizing renal function in patients with bilat-
eral WT [19, 20]. Hubertus et al. showed that hypertension is
less common in patients with bilateral WTafter bilateral NSS.
At the same time, rates of local relapse or disease-associated
Table 3 Renal function ofWilms
tumor survivors at a follow-up of
15 years compared with the
KIMONO cohort
Wilms tumor KIMONO p
Number 31 57
Age 17.8 (SD 3.6) 15.4 (SD 2.9) 0.002
Systolic blood pressure (z-score) 0.7 (SD 1.5) 0.3 (SD 1.1) 0.3
Diastolic blood pressure (z-score) 0.0 (SD 0.7) 0.0 (SD 0.8) 0.9
High blood pressure 6/23 (26 %) 6/57 (11 %) 0.08
eGFR (ml*min−1*1.73 m−2) 83 (SD 14) 89 (SD 31) 0.2
eGFR <60 ml*min−1*1.73 m−2 1/24 (4 %) 7/57 (12 %) 0.3
Proteinuria ND 25/57 (44 %)
Anti-hypertensive and/or anti-proteinuric drug use 0/31 (0 %) 20/57 (35 %) <0.001
Renal injury 7/31 (23 %) 31/57 (54 %) 0.004
Renal injury was defined as high blood pressure, proteinuria, and/or the use of drugs treating either condition,
and/or eGFR<60 ml*min−1 *1.73 m−2
Data are presented as mean (standard deviation, SD) or as number (%)
eGFR estimated glomerular filtration rate, ND not determined
Table 4 Frequency of progressive renal injury at the latest follow-up in Wilms tumor survivors based on published cohorts since 2005










Cozzi et al. 2005 [28] 16 6.0 (SD 3.4) 2/16 (12.5 %) 2/16 (12.5 %) NR NR NR
Daw et al. 2009 [29] 11 11.2 2/11 (18.2 %) 2/11 (18.2 %) NR NR NR
Stefanowicz et al. 2011 [30] 32 9.3 (SD 5.4) 2/32 (6.3 %) 7/32 (21.9 %) 0/32 0/32 NR
Sanpakit et al. 2013 [31] 17 4.8 NR NR NR 2/17 (11.8 %) NR
Elli et al. 2013 [32] 25 9.9 3/15 (20.0 %) NR 0/25 0/25 NR
Kern et al. 2014 [33] 55 6.3 NR NR NR 2/55 (3.6 %) NR
Spreafico et al. 2014 [34] 15 13.3 0/15 2/15 NR 0/15 NR
Kishore et al. 2015 [35] 29 4.8 (SD 2.6) 2/29 (6.9 %) 1/29 (3.4 %) NR 1/29 (3.4 %) NR
Current report 31 14.8 (SD 3.3) 6/23 (26.1 %) NR 0/31 1/24 (4.2 %) 7/31 (22.6 %)
Overall 231 17/141 (12.1%) 14/103 (13.6%) 0/88 6/197 (3.0%)
eGFR estimated glomerular filtration rate, NR not reported
a Renal injury was defined as a reduced eGFR (<60 ml*min−1 *1.73 m−2 ), proteinuria/albuminuria, and/or hypertension, and/or drug use to treat either
proteinuria and/or hypertension
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death were equal to those of patients with bilateral WT and
unilateral NSS and contralateral nephrectomy, suggesting
NSS to be oncologically safe [21]. A recent Surveillance, Ep-
idemiology, and End Results (SEER) analysis on the use of
NSS and the impact on survival in children with WT also con-
cluded that overall survival was similar between NSS and rad-
ical nephrectomy in a cohort of both bilateral and unilateralWT
patients [22]. Cost et al. compared renal function outcomes after
NSS and radical nephrectomy in nonsyndromic unilateral WT
patients only. EGFR at last follow-up was equal in the two
groups [23]. Data from the Internatioanal Society of Pediatric
Oncology (SIOP) 2001 study showed that NSS was only per-
formed in 3 % of patients with unilateral WT (65 % in stage I
tumors). The authors concluded that despite excellent survival
with few relapses, the gain of nephrons needs to be weighed
against the risk of inducing stage III with intensified therapy
[24]. Studies on renal function after NSS are based on relatively
small patient groups and are all of a retrospective nature. Larger
prospective studies are needed to fully address the gain of renal
function versus oncological outcome in NSS.
Preserving renal function may serve another important
goal, namely preventing cardiovascular complications.
Cardiorenal syndrome is defined as a pathological disorder
of the heart and kidneys in which acute or chronic dysfunction
in one organ may induce acute or chronic dysfunction in the
other organ. It includes a broad spectrum of diseases in which
the heart and kidney are both involved [25]. Patients with
chronic kidney disease are at a higher risk of mortality than
the general population. The renal dysfunction represents an
independent risk factor for cardiovascular disease, as these
patients present higher mortality rates for myocardial infarc-
tion and sudden death [26, 27].
Our study has several limitations. First of all, our study has
a retrospective design. As a pre-defined follow-up schedule
has only been implemented in the last few years, data were
missing from a different number of patients at each time-point.
In addition, some data were retrieved from other hospitals,
where other methods and reference values may have been
used. BPwasmeasuredmanually at the beginning of the study
period, and by using oscillometric methods (DynaMap) for
the last few years. Unfortunately, information on the method
of measurement is not mentioned in the patient record, which
may have an effect on the results. In addition, BP used to be
measured only once, whereas it is measured three times in the
current follow-up protocol. Analogous to the guideline that
was presented for children with an SFK [17], we suggest a
similar follow-up protocol for WT survivors with an SFK
(Table 5).
Conclusion
In a similar fashion to children with an SFK for non-oncological
reasons, progressive renal injury presents in WT survivors, but
the incidence is lower. However, renal injury in our cohorts may
have been underestimated owing to the absence of information
on proteinuria in WT survivors. As with patients with a non-
malignant SFK, long-term follow-up is essential to monitor,
inform, and prevent disease sequelae for WT survivors. A stan-
dardized follow-up protocol (including urinalysis) has been put
in place to optimize follow-up.
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